

# ACT Onco<sup>®</sup> + Report

PATIENT		
Identifier: 林煜婷		Patient ID: 47496004
Date of Birth: Sep 10, 1985		Gender: Female
Diagnosis: Colon cancer		
ORDERING PHYSICIAN		
Name: 陳明晃醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11155183C	Collection site: Lung	Type: FFPE tissue
Date received: Feb 10, 2023	Lab ID: AA-23-00862	D/ID: NA

## ABOUT ACT Onco<sup>®</sup>+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) ( $\leq 15$  nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

## SUMMARY FOR ACTIONABLE VARIANTS

### VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
KRAS Q61L	-	Cetuximab, Panitumumab	-

### VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
KRAS Q61L	-	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib

#### Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

# ACT Onco<sup>®</sup> + Report

## TESTING RESULTS

### VARIANT(S) WITH CLINICAL RELEVANCE

#### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
APC	L1302fs	80.1%
ERCC4	C723*	36.1%
KRAS	Q61L	56.6%
TP53	R342*	82.0%

#### - Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr17	FLCN, TP53	Heterozygous deletion	1
Chr18	SMAD4	Heterozygous deletion	1
Chr3	ATR	Heterozygous deletion	1
Chr5	RAD50	Heterozygous deletion	1

#### - Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

#### - Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	1.9 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

#### Note:

- Variant(s) enlisted in the SNV table may currently exhibit no relevance to treatment response prediction. Please refer to INTERPRETATION for more biological information and/or potential clinical impacts of the variants.
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 59% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco<sup>®</sup> to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at  $\geq 7.5$  mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is  $< 30\%$ .

# ACT Onco<sup>®</sup> + Report

## THERAPEUTIC IMPLICATIONS TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
<b>Level 1</b>		
<b>KRAS Q61L</b>	Cetuximab, Panitumumab	<b>resistant</b>
<b>Level 3A</b>		
<b>KRAS Q61L</b>	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib	<b>resistant</b>

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
<b>1</b>	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
<b>2</b>	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
<b>3A</b>	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
<b>3B</b>	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
<b>4</b>	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

# ACT Onco<sup>®</sup> + Report

## IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

### - Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

## CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

## HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

## OTHERS

### Pharmacogenomic implication

Gene	Detection Site	Genotype	Drug Impact	Level of Evidence*
UGT1A1	rs4148323	AG	Irinotecan-based regimens	Level 1B

#### Clinical Interpretation:

Patients with the AG genotype and cancer who are treated with irinotecan-based regimens may have an increased risk of diarrhea and neutropenia as compared to patients with the GG genotype, or a decreased risk of diarrhea and neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of diarrhea and neutropenia.

\* Level of evidence was defined by PharmGKB (<https://www.pharmgkb.org/page/clinAnnLevels>)

**Level 1A:** Clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation.

**Level 1B:** Clinical annotations describe variant-drug combinations with a high level of evidence supporting the association but no variant-specific prescribing guidance in an annotated clinical guideline or FDA drug label.

**Level 2A:** Variants in Level 2A clinical annotations are found in PharmGKB's Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely.

#### Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

# ACT Onco<sup>®</sup> + Report

## VARIANT INTERPRETATION

### APC L1302fs

#### Biological Impact

APC (adenomatous polyposis coli) gene encodes a negative regulator of the WNT/ $\beta$ -catenin signaling pathway. It binds to  $\beta$ -catenin, leading to its degradation and subsequently inhibits transcriptional activation<sup>[1]</sup>. APC is also associated with cell migration and adhesion, apoptosis, and DNA repair<sup>[2][3]</sup>. APC mutations are commonly observed in colorectal cancer and are also reported in lung, breast, prostate, uterine, skin, bladder, stomach and head and neck cancers (cBioPortal, MSKCC, April 2015). L1302fs mutation results in a change in the amino acid sequence beginning at 1302, likely to cause premature truncation of the functional APC protein (UniProtKB). This mutation is predicted to lead to a loss of APC protein function, despite not being characterized in the literature.

#### Therapeutic and prognostic relevance

A study of colorectal cancer patients (n= 468) indicated that MSS tumors without any APC mutation carry a worse prognosis than single APC mutation tumors. However, tumors with two APC, KRAS, and TP53 mutations confer the poorest survival among all the subgroups examined<sup>[4]</sup>.

### ERCC4 C723\*

#### Biological Impact

The ERCC4 (XPF) gene encodes a subunit of the ERCC1-XPF nuclease which plays an essential role in DNA repair and maintaining genomic stability. Loss-of-function mutations in ERCC4 are associated with several rare inherited human disorders such as Fanconi anemia which leads to bone marrow failure and predisposition to cancer<sup>[5]</sup>.

C723\* mutation results in a premature truncation of the ERCC4 protein at amino acid 723 (UniProtKB). This mutation is predicted to lead to a loss of ERCC4 function, despite not having characterized in the literature.

#### Therapeutic and prognostic relevance

A patient with stage IIIC high-grade serous ovarian cancer harboring inactivation mutation of ERCC4 was sensitive to platinum-based chemotherapy. However, ERCC4 inactivation does not confer sensitivity to rucaparib and doxorubicin in vitro<sup>[6]</sup>. ERCC4 mutation has been determined as an inclusion criterion for the trials evaluating niraparib efficacy in solid tumors (NCT03207347) and olaparib efficacy in metastatic urothelial cancer (NCT03448718).

### KRAS Q61L

#### Biological Impact

The V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (KRAS) gene encodes a small GTPase protein, a member of the RAS family of small GTPases, which catalyze the hydrolysis of GTP to GDP. RAS proteins cycle between an active (GTP-bound) and an inactive (GDP-bound) state, to activate the downstream oncogenic pathways, including the PI3K/AKT/mTOR and MAPK pathways<sup>[7]</sup>. KRAS mutations occur primarily in three hotspots G12, G13 and Q61, and less frequently in codon A146<sup>[7][8]</sup>. These are activating mutations that lead to constitutive activation and persistent stimulation of the downstream signaling pathways<sup>[9][10]</sup>. Mutations in KRAS have been reported in a diverse spectrum of human malignancies, including pancreatic carcinomas (>80%)<sup>[7][11]</sup>, colon carcinomas (40-50%)<sup>[12][13]</sup>, and lung carcinomas (30-50%)<sup>[14][15]</sup>, but are also present in biliary tract malignancies, endometrial cancer, cervical cancer, bladder cancer, liver cancer, myeloid leukemia and breast cancer<sup>[8]</sup>.

KRAS Q61L is a hotspot mutation lies within the GTP-binding region of the KRAS protein (UniProtKB). Q61L results in decreased KRAS GTPase activity, increased activation of ERK, and induce cell transformation in vitro<sup>[16][17]</sup>.

# ACT Onco<sup>®</sup> + Report

## Therapeutic and prognostic relevance

Except for KRAS G12C, other KRAS mutants are not currently targetable, but the downstream MEK serves as a potential target<sup>[18]</sup>. MEK inhibitors trametinib, cobimetinib, and binimetinib were approved by the U.S. FDA for patients with advanced metastatic melanoma whose tumors harbor BRAF V600 mutations<sup>[19][20][21][22]</sup>.

There are case reports indicated that patients harboring a KRAS mutation may benefit from MEK inhibitor treatment. A patient with small cell neuroendocrine carcinoma (SCNEC) of the cervix harboring a KRAS G12D mutation showed significant response with trametinib<sup>[23]</sup>. Another low-grade serous carcinoma case with KRAS G12D also has sustained response to trametinib (Am J Clin Exp Obstet Gynecol 2015;2(3):140-143). In addition, a low-grade serous ovarian cancer patient harboring KRAS G12V mutation showed stable disease after 8 weeks of binimetinib treatment, and demonstrated a partial response after another 26 weeks of treatment<sup>[24]</sup>. However, trametinib did not demonstrate superiority to docetaxel in KRAS-mutant non-small cell lung cancer (NSCLC) patients, based on results from a randomized Phase II study<sup>[25]</sup>.

Both clinical and preclinical studies demonstrated a limited response to monotherapy using MEK inhibitors<sup>[26]</sup>. Moreover, several clinical trials are in progress to evaluate the combination of MEK and mTOR inhibition as a new potential therapeutic strategy in CRC<sup>[27]</sup>, and in patient-derived xenografts of RAS-mutant CRC, inhibition of MEK and mTOR suppressed tumor growth, but not tumor regression<sup>[28]</sup>. A study using the CRC patient-derived xenograft (PDX) model showed that the combination of trametinib, a MEK inhibitor, and palbociclib, a CDK4/6 inhibitor, was well tolerated and resulted in objective responses in all KRAS mutant models<sup>[29]</sup>.

KRAS mutation has been determined as an inclusion criterion for the trials evaluating MEK inhibitors efficacies in various types of solid tumors (NCT03704688, NCT02399943, NCT02285439, NCT03637491, NCT04214418).

Cetuximab and panitumumab are two EGFR-specific antibodies approved by the U.S. FDA for patients with KRAS wild-type metastatic colorectal cancer (NCT00154102, NCT00079066, NCT01412957, NCT00364013). Results from the PRIME and FIRE-3 trials indicated that panitumumab and cetuximab did not benefit patients with KRAS or NRAS mutations and may even have a detrimental effect in these patients<sup>[30]</sup>. Taken together, the National Comprehensive Cancer Network (NCCN) recommended that, cetuximab and panitumumab should only be used if both KRAS and NRAS genes are normal (NCCN guidelines)<sup>[31][32]</sup>. Numerous studies have demonstrated the presence of KRAS or NRAS mutations at exon 2, 3 or 4 as a predictor of resistance to anti-EGFR therapies<sup>[33][34][35][36][37][38][39]</sup>.

Sorafenib, a multi-kinase inhibitor, has been shown to be beneficial in KRAS-mutant CRC<sup>[40]</sup>, KRAS-mutant NSCLC<sup>[41]</sup>, and KRAS-amplified melanoma<sup>[42]</sup>.

There has been conflicting data on the effect of KRAS mutation on the efficacy of bevacizumab in metastatic CRC patients (J Clin Oncol 34, 2016 (suppl; abstr 3525))<sup>[43][44]</sup>.

In NCCN guidelines for NSCLC, KRAS mutations have been suggested as an emerging biomarker for EGFR TKIs in NSCLC patients. KRAS mutations are associated with a lack of efficacy of EGFR TKIs, including erlotinib, gefitinib, afatinib, and osimertinib, in NSCLC patients<sup>[45][46][47]</sup>.

Studies have shown that KRAS mutation, especially those occurs in exon 2 (codon 12 or 13) and codon 61 indicated a poor prognosis for patients with CRC<sup>[48]</sup>.

In low-grade serous carcinoma of the ovary or peritoneum, patients with KRAS or BRAF mutations (n=21) had a significantly better OS than those with wild-type KRAS or BRAF (n=58) (106.7 months vs 66.8 months), respectively<sup>[49]</sup>. In ovarian serous borderline tumor with recurrent low-grade serous carcinoma, patient harboring KRAS G12V mutation appeared to have shorter survival time<sup>[50]</sup>.



# ACT Onco<sup>®</sup> + Report

## TP53 R342\*, Heterozygous deletion

### Biological Impact

TP53 encodes the p53 protein, a crucial tumor suppressor that orchestrates essential cellular processes including cell cycle arrest, senescence and apoptosis<sup>[51]</sup>. TP53 is a proto-typical haploinsufficient gene, such that loss of a single copy of TP53 can result in tumor formation<sup>[52]</sup>.

R342\* mutation results in a premature truncation of the p53 protein at amino acid 342 (UniProtKB). This mutation is predicted to lead to a loss of p53 function, despite not having characterized in the literature. Loss of the second wild-type allele resulted in the biallelic inactivation of the gene.

### Therapeutic and prognostic relevance

Despite having a high mutation rate in cancers, there are currently no approved targeted therapies for TP53 mutations. A phase II trial demonstrated that Wee1 inhibitor (AZD1775) in combination with carboplatin was well tolerated and showed promising anti-tumor activity in TP53-mutated ovarian cancer refractory or resistant (< 3 months) to standard first-line therapy (NCT01164995)<sup>[53]</sup>.

In a retrospective study (n=19), advanced sarcoma patients with TP53 loss-of-function mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with pazopanib<sup>[54]</sup>. Results from another Phase I trial of advanced solid tumors (n=78) demonstrated that TP53 hotspot mutations are associated with better clinical response to the combination of pazopanib and vorinostat<sup>[55]</sup>.

Advanced solid tumor and colorectal cancer patients harboring a TP53 mutation have been shown to be more sensitive to bevacizumab when compared with patients harboring wild-type TP53<sup>[56][57][58]</sup>. In a pilot trial (n=21), TP53-negative breast cancer patients demonstrated increased survival following treatment with bevacizumab in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel)<sup>[59]</sup>. TP53 mutations were correlated with poor survival of advanced breast cancer patients receiving tamoxifen or primary chemotherapy<sup>[60][61]</sup>. In a retrospective study of non-small cell lung cancer (NSCLC), TP53 mutations were associated with high expression of VEGF-A, the primary target of bevacizumab, offering a mechanistic explanation for why patients exhibit improved outcomes after bevacizumab treatment when their tumors harbor mutant TP53 versus wild-type TP53<sup>[62]</sup>.

## ATR Heterozygous deletion

### Biological Impact

Ataxia Telangiectasia and Rad3-related protein (ATR) gene encodes a serine/threonine kinase that is involved in the DNA damage response. ATR plays as a central coordinator of the DNA damage response (DDR) by responding to single-stranded regions of the DNA<sup>[63][64]</sup> and the maintenance of genome stability<sup>[65]</sup>. ATR has also been implicated as a haploinsufficient tumor suppressor with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions<sup>[66][67]</sup>. Germline mutation of ATR is associated with cancer predisposition and Seckel syndrome, a condition associated with CNS disorders<sup>[68][69]</sup>. Somatic mutations of ATR are associated with microsatellite instability and are found in colorectal cancer<sup>[70]</sup>, urothelial cancer<sup>[71]</sup>, gastric cancer<sup>[72]</sup>, endometrial cancer<sup>[73]</sup> and myelomas<sup>[74]</sup>.

### Therapeutic and prognostic relevance

In a clinical study, a metastatic castration-resistant prostate cancer patient harboring deleterious mutation in the ATR gene (K2106fs) had a PSA remission of 62% and PSA-PFS of 13 months by olaparib treatment<sup>[75]</sup>.

ATR has been determined as an inclusion criterion for the trials evaluating olaparib efficacy in ovarian cancer<sup>[76]</sup> and advanced solid tumors (NCT03297606; CAPTUR trial), rucaparib efficacy in ovarian cancer<sup>[77]</sup>, niraparib efficacy in pancreatic cancer (NCT03553004), and any malignancy, except prostate (NCT03207347), and talazoparib efficacy in

# ACT Onco<sup>®</sup> + Report

HER2-negative solid tumors (NCT02401347), prostate cancer (NCT03148795), and lung cancer (NCT03377556), respectively.

## FLCN Heterozygous deletion

### Biological Impact

The FLCN gene encodes the tumor suppressor, Folliculin, a GTPase activating protein (GAP) for RagC/D GTPase proteins involved in amino acid sensing and signaling to mTORC1<sup>[78]</sup>. FLCN has been implicated as a haploinsufficient gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions<sup>[79][80]</sup>. Inactivation of the FLCN gene by mutation or deletion results in the activation of the mTOR pathway and AKT signaling<sup>[81][82]</sup>. Germline mutation of the FLCN gene causes the Birt-Hogg-Dubé syndrome, a rare disorder that is characterized by benign hamartomatous skin lesions and an increased risk of pneumothorax and renal tumors<sup>[83]</sup>.

### Therapeutic and prognostic relevance

In a prospective Phase 2 study, four anaplastic thyroid cancer (ATC)/ poorly differentiated thyroid cancer (PDTC) patients who had PI3K/mTOR/AKT alterations, including TSC2, FLCN or NF1, showed impressive progression-free survival (PFS) of 15.2 months after receiving everolimus<sup>[84]</sup>. mTOR inhibition via rapamycin also demonstrated potential in inhibiting the growth of renal cells deficient in FLCN in the preclinical setting<sup>[85]</sup>.

## RAD50 Heterozygous deletion

### Biological Impact

The RAD50 gene encodes a highly-conserved DNA double-strand break (DSB) repair factor. It forms MRN complex with NBS1 and MRE11 protein and is involved in sensing and early processing of DSB, cell cycle checkpoints, DNA recombination and maintenance of telomeres<sup>[86][87]</sup>. Mutations in the components of the MRN complex could increase susceptibility to familial breast cancer<sup>[88][89]</sup>, gastric cancer<sup>[90]</sup>, colorectal cancer<sup>[91]</sup>, and urothelial cancer<sup>[92]</sup>. RAD50 has been implicated as a haploinsufficient gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions<sup>[93]</sup>. Besides, RAD50 deletion was also suggested as a marker of BRCAness, a phenotype shared between non-BRCA1/2-mutated ovarian cancers and BRCA1/2-mutated ovarian cancers<sup>[94]</sup>.

### Therapeutic and prognostic relevance

Preclinical data showed that knockdown of the RAD50 gene in ovarian cancer cell lines was significantly associated with better responses to two PARP inhibitors, olaparib and rucaparib<sup>[94]</sup>. RAD50 has been selected as an inclusion criterion for the trials examining talazoparib efficacy in HER2-negative breast cancer, olaparib efficacy in breast cancer, rucaparib efficacy in metastatic prostate cancer and niraparib efficacy in any malignancy (except prostate) (NCT02401347, NCT03207347, NCT03344965, NCT03413995).

## SMAD4 Heterozygous deletion

### Biological Impact

The SMAD family member 4 (SMAD4) gene encodes a transcription factor that acts as a downstream effector in the TGF- $\beta$  signaling pathway. Upon phosphorylated and activated by serine-threonine receptor kinase, Smad4 is the Co-Smad which recruits other activated R-Smad proteins to the Smad transcriptional complex and regulate TGF- $\beta$ -targeted genes<sup>[95]</sup>. Smad4 has been identified as a haploinsufficient gene with one copy loss may lead to a weak protein expression and is insufficient to execute its original physiological function<sup>[96]</sup>. SMAD4 germline mutations are associated with juvenile polyposis syndrome (JPS)<sup>[97][98][99][100]</sup>. Somatic mutations of SMAD4 are commonly observed in pancreatic cancer<sup>[101]</sup>, colorectal cancer (CRC)<sup>[99][102][103]</sup>, and less frequently seen in other cancers such as lung adenocarcinoma<sup>[104]</sup>, head and neck cancer<sup>[105][106]</sup>, and cutaneous squamous cell carcinoma<sup>[107]</sup>.



# ACT Onco<sup>®</sup> + Report

## Therapeutic and prognostic relevance

In Chinese patients with metastatic colorectal cancer, SMAD4 or NF1 mutations are suggested as a potential biomarker for poor prognosis to cetuximab-based therapy<sup>[108]</sup>. Preclinical data demonstrated that depletion of SMAD4 by shRNA knockdown increased clonogenic survival and cetuximab resistance in HPV-negative head and neck squamous cell carcinoma cells<sup>[109]</sup>.

SMAD4 is also suggested as a predictive marker for 5-fluorouracil-based chemotherapy in colorectal cancer (CRC)<sup>[110][111]</sup>. CRC patients with normal SMAD4 diploidy exhibited three-fold higher benefit of 5-FU/mitomycin-based adjuvant therapy when compared with those with SMAD4 deletion<sup>[112]</sup>.

Results from clinical and meta-analyses showed that loss of SMAD4 in CRC, pancreatic cancer was correlated with poor prognosis<sup>[113][114][115][116][117][118][119][120]</sup>. In cervical cancer patients, weak cytoplasmic SMAD4 expression and absent nuclear SMAD4 expression were shown to be significantly associated with poor disease-free and overall 5-year survival<sup>[121]</sup>.

# ACT Onco<sup>®</sup> + Report

## US FDA-APPROVED DRUG(S)

### Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

### - FDA Approval Summary of Everolimus (AFINITOR)

<b>RADIANT-4</b> <sup>[122]</sup> NCT01524783	<b>Lung or gastrointestinal neuroendocrine tumor</b> (Approved on 2016/02/26)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
<b>BOLERO-2</b> <sup>[123]</sup> NCT00863655	<b>Breast cancer</b> (Approved on 2012/07/20)
	<b>ER+/HER2-</b> Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
<b>EXIST-2</b> NCT00790400	<b>Tuberous sclerosis complex (tsc)-associated renal angiomyolipoma</b> (Approved on 2012/04/26)
	- Everolimus vs. Placebo [ORR(%): 41.8 vs. 0]
<b>RADIANT-3</b> <sup>[124]</sup> NCT00510068	<b>Pancreatic neuroendocrine tumor</b> (Approved on 2011/05/05)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
<b>EXIST-1</b> <sup>[125]</sup> NCT00789828	<b>Subependymal giant cell astrocytoma</b> (Approved on 2010/10/29)
	- Everolimus vs. Placebo [ORR(%): 35.0]
<b>RECORD-1</b> <sup>[126]</sup> NCT00410124	<b>Renal cell carcinoma</b> (Approved on 2009/05/30)
	- Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

### Niraparib (ZEJULA)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

### - FDA Approval Summary of Niraparib (ZEJULA)

<b>PRIMA</b> NCT02655016	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2020/04/29)
	- Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2]
<b>NOVA</b> <sup>[127]</sup> NCT01847274	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/03/27)
	- Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7]

# ACT Onco<sup>®</sup> + Report

## Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

### - FDA Approval Summary of Olaparib (LYNPARZA)

<b>OlympiA</b> NCT02032823	<b>Her2-negative high-risk early breast cancer</b> (Approved on 2022/03/11)
	<b>HER2-/gBRCA mutation</b> Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M): ]
<b>PROfound</b> <sup>[128]</sup> NCT02987543	<b>Prostate cancer</b> (Approved on 2020/05/19)
	<b>HRR genes mutation</b> Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
<b>PAOLA-1</b> <sup>[129]</sup> NCT02477644	<b>Ovarian cancer</b> (Approved on 2020/05/08)
	<b>HRD+</b> Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
<b>POLO</b> <sup>[130]</sup> NCT02184195	<b>Pancreatic adenocarcinoma</b> (Approved on 2019/12/27)
	<b>gBRCA mutation</b> Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
<b>SOLO-1</b> <sup>[131]</sup> NCT01844986	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2018/12/19)
	<b>gBRCA mutation or sBRCA mutation</b> Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
<b>OlympiAD</b> <sup>[132]</sup> NCT02000622	<b>Breast cancer</b> (Approved on 2018/02/06)
	<b>HER2-/gBRCA mutation</b> Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
<b>SOLO-2/ENGOT-Ov21</b> <sup>[133]</sup> NCT01874353	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/08/17)
	<b>gBRCA mutation</b> Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
<b>Study19</b> <sup>[134]</sup> NCT00753545	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/08/17)
	- Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]

## Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

### - FDA Approval Summary of Rucaparib (RUBRACA)

<b>TRITON2</b> NCT02952534	<b>Prostate cancer</b> (Approved on 2020/05/15)
	<b>gBRCA mutation or sBRCA mutation</b> Rucaparib [ORR(%): 44.0, DOR(M): NE]
<b>ARIEL3</b> <sup>[77]</sup> NCT01968213	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2018/04/06)
	- Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]

# ACT Onco<sup>®</sup> + Report

## Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

### - FDA Approval Summary of Talazoparib (TALZENNA)

EMBRACA <sup>[135]</sup> NCT01945775	<b>Breast cancer</b> (Approved on 2018/10/16)
	<b>HER2-/gBRCA mutation</b>
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

## Temsirolimus (TORISEL)

Temsirolimus is a soluble ester of sirolimus (rapamycin, brand-name drug Rapamune) and functions as an inhibitor of mammalian target of rapamycin complex (mTORC). The inhibitory molecular mechanism is similar to Everolimus. Temsirolimus is developed by Wyeth Pharmaceuticals and marketed by Pfizer under the trade name TORISEL.

### - FDA Approval Summary of Temsirolimus (TORISEL)

[136] NCT00065468	<b>Renal cell carcinoma</b> (Approved on 2007/05/30)
	-
	Temsirolimus vs. Ifn- $\alpha$ [OS(M): 10.9 vs. 7.3]

D=day; W=week; M=month

# ACT Onco<sup>®</sup> + Report

## ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.



# ACT Onco<sup>®</sup> + Report


## SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
APC	L1302fs	16	c.3904del	NM_000038	COSM18954	80.1%	760
ERCC4	C723*	11	c.2169C>A	NM_005236	-	36.1%	2037
KRAS	Q61L	3	c.182A>T	NM_004985	COSM553	56.6%	1331
TP53	R342*	10	c.1024C>T	NM_000546	COSM11073	82.0%	300

### - Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



# ACT Onco<sup>®</sup> + Report

## OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ALK	R1084H	20	c.3251G>A	NM_004304	-	54.8%	1132
BRAF	V413M	10	c.1237G>A	NM_004333	COSM7346645	95.3%	1401
CTCF	K530T	9	c.1589A>C	NM_006565	-	22.1%	1254
DOT1L	Splice region	-	c.1660-8G>A	NM_032482	-	36.3%	628
DOT1L	G1252S	27	c.3754G>A	NM_032482	COSM6648701	25.4%	319
EPCAM	L78R	3	c.233T>G	NM_002354	-	37.7%	584
GNAS	D575A	1	c.1724A>C	NM_080425	-	24.2%	549
IKBKE	V68I	4	c.201_202inv	NM_014002	-	28.7%	861
MUC16	D12307N	16	c.36919G>A	NM_024690	-	39.1%	371
MUC16	S9527G	3	c.28579A>G	NM_024690	-	34.6%	1225
PIK3C2G	E1260D	28	c.3780G>T	NM_004570	-	35.8%	1981
RB1	I348T	10	c.1043T>C	NM_000321	-	62.9%	442
RECQL4	R372T	5	c.1115G>C	NM_004260	-	82.5%	610
ROS1	Y1239F	24	c.3716A>T	NM_002944	-	49.1%	1651
SYNE1	R1673W	38	c.5017C>T	NM_182961	-	44.2%	830


Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

# ACT Onco<sup>®</sup> + Report

## TEST DETAILS

### SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Dec 29, 2022
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11155183C
- Collection site: Lung
- Examined by: Dr. Yun-An Chen
  1. The percentage of viable tumor cells in total cells in the whole slide (%): 30%
  2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 60%
  3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 10%
  4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 20%
  5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

## RUN QC

- Panel: ACTOnco<sup>®</sup>+

### DNA test

- Mean Depth: 926x
- Target Base Coverage at 100x: 95%

### RNA test

- Average unique RNA Start Sites per control GSP2: 190

# ACT Onco<sup>®</sup> + Report

## LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

## NEXT-GENERATION SEQUENCING (NGS) METHODS

### DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage  $\geq 20$ , allele frequency  $\geq 5\%$  and actionable variants with allele frequency  $\geq 2\%$  were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at  $100\times \geq 85\%$  with a mean coverage  $\geq 500\times$ .

Variants reported in Genome Aggregation database with  $> 1\%$  minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation  $\geq 0.3$  were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco<sup>®</sup> to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to  $\geq 7.5$  mutations per megabase (Muts/Mb); TMB-Low corresponds to  $< 7.5$  Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is  $< 30\%$ .

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in  $> 400$  genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

### RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be  $\geq 10$ .

# ACT Onco<sup>®</sup> + Report

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2  $\geq 3$ ; (2) Number of supporting reads spanning the fusion junction  $\geq 5$ ; (3) Percentage of supporting reads spanning the fusion junction  $\geq 10\%$ ; (4) Fusions annotated in Quiver Gene Fusion Database.

## DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

## Variant Analysis:

醫藥資訊研究員  
楊杭哲 博士  
Hang-Che Yang Ph.D.



## Sign Off

解剖病理專科醫師王業翰  
Yeh-Han Wang M.D.  
病解字第 000545 號





# ACT Onco<sup>®</sup> + Report

## GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTB	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBK	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLC01B1*
SLC01B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

\*Analysis of copy number alterations NOT available.

## FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------


# ACT Onco<sup>®</sup> + Report

## APPENDIX


### POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Gene	Therapies	Possible effect
FLCN	Everolimus, Temsirolimus	sensitive
ATR	Niraparib, Olaparib, Rucaparib, Talazoparib	sensitive
RAD50	Niraparib, Olaparib, Rucaparib, Talazoparib	sensitive
SMAD4	Cetuximab	resistant

### SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Olaparib, Niraparib, Rucaparib, Talazoparib



1: Everolimus, Temsirolimus

# ACT Onco<sup>®</sup> + Report

## DISCLAIMER

### 法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

### 醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

### 基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

### 證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

### 責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

# ACT Onco<sup>®</sup> + Report

## REFERENCE

1. PMID: 24200292; 2014, Curr Drug Targets;15(1):90-102  
Exploiting APC function as a novel cancer therapy.
2. PMID: 18848448; 2008, Trends Cell Biol;18(12):587-96  
APC shuttling to the membrane, nucleus and beyond.
3. PMID: 18662849; 2008, Cancer Lett;271(2):272-80  
A novel function of adenomatous polyposis coli (APC) in regulating DNA repair.
4. PMID: 27302369; 2016, Nat Commun;7():11743  
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.
5. PMID: 26074087; 2015, Gene;569(2):153-61  
The ERCC1 and ERCC4 (XPF) genes and gene products.
6. PMID: 25634215; 2015, Cancer Res;75(4):628-34  
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
7. PMID: 2453289; 1988, Cell;53(4):549-54  
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.
8. PMID: 2114981; 1990, Eur J Clin Invest;20(3):225-35  
ras oncogenes: their role in neoplasia.
9. PMID: 20617134; 2010, J Biomed Biotechnol;2010():150960  
Clinical relevance of KRAS in human cancers.
10. PMID: 21993244; 2011, Nat Rev Cancer;11(11):761-74  
RAS oncogenes: weaving a tumorigenic web.
11. PMID: 3047672; 1988, Nucleic Acids Res;16(16):7773-82  
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.
12. PMID: 3587348; 1987, Nature;327(6120):293-7  
Prevalence of ras gene mutations in human colorectal cancers.
13. PMID: 1942608; 1991, Nihon Shokakibyo Gakkai Zasshi;88(8):1539-44  
[Prevalence of K-ras gene mutations in human colorectal cancers].
14. PMID: 2252272; 1990, Am Rev Respir Dis;142(6 Pt 2):S27-30  
The ras oncogenes in human lung cancer.
15. PMID: 1486840; 1992, Environ Health Perspect;98():13-24  
Role of proto-oncogene activation in carcinogenesis.
16. PMID: 26854029; 2016, Nat Commun;7():10647  
KRAS insertion mutations are oncogenic and exhibit distinct functional properties.
17. PMID: 25437878; 2015, J Clin Invest;125(1):222-33  
Rare codons capacitate Kras-driven de novo tumorigenesis.
18. PMID: 25414119; 2014, Drugs;74(18):2111-28  
The biology and clinical development of MEK inhibitors for cancer.
19. PMID: 25265492; 2014, N Engl J Med;371(20):1877-88  
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

# ACT Onco<sup>®</sup> + Report

20. PMID: 22663011; 2012, N Engl J Med;367(2):107-14  
Improved survival with MEK inhibition in BRAF-mutated melanoma.
21. PMID: 25265494; 2014, N Engl J Med;371(20):1867-76  
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
22. PMID: 29573941; 2018, Lancet Oncol;19(5):603-615  
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
23. PMID: 26075998; 2014, Gynecol Oncol Rep;10():28-9  
Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation.
24. PMID: 29946554; 2018, Gynecol Oncol Rep;25():41-44  
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.
25. PMID: 25722381; 2015, Ann Oncol;26(5):894-901  
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
26. PMID: 24947927; 2014, Clin Cancer Res;20(16):4251-61  
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
27. PMID: 27340376; 2016, Curr Colorectal Cancer Rep;12():141-150  
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.
28. PMID: 22392911; 2012, Clin Cancer Res;18(9):2515-25  
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
29. PMID: 26369631; 2016, Clin Cancer Res;22(2):405-14  
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
30. PMID: 25937522; 2015, Eur J Cancer;51(10):1243-52  
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.
31. PMID: 19188670; 2009, J Clin Oncol;27(12):2091-6  
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
32. PMID: 18802721; 2008, Virchows Arch;453(5):417-31  
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
33. PMID: 25605843; 2015, J Clin Oncol;33(7):692-700  
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
34. PMID: 27422777; 2016, Tumour Biol;37(9):11645-11655  
Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
35. PMID: 24024839; 2013, N Engl J Med;369(11):1023-34  
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
36. PMID: 24666267; 2014, Acta Oncol;53(7):852-64  
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
37. PMID: 27722750; 2017, JAMA Oncol;3(2):194-201  
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective



# ACT Onco<sup>®</sup> + Report

Analyses of the CRYSTAL and FIRE-3 Trials.

38. PMID: 27736842; 2016, Br J Cancer;115(10):1206-1214  
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
39. PMID: 20921465; 2010, J Clin Oncol;28(31):4697-705  
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
40. PMID: 24407191; 2014, Br J Cancer;110(5):1148-54  
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
41. PMID: 23224737; 2013, Clin Cancer Res;19(3):743-51  
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIB or IV) non-small cell lung cancer with a KRAS mutation.
42. PMID: 26307133; 2016, Clin Cancer Res;22(2):374-82  
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
43. PMID: 23828442; 2013, Med Oncol;30(3):650  
KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.
44. PMID: 28632865; 2017, JAMA;317(23):2392-2401  
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
45. PMID: 18349398; 2008, J Clin Oncol;26(9):1472-8  
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
46. PMID: 23401440; 2013, J Clin Oncol;31(8):1112-21  
KRAS mutation: should we test for it, and does it matter?
47. PMID: 18024870; 2007, J Clin Oncol;25(33):5240-7  
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
48. PMID: 15923428; 2005, Ann Oncol;16 Suppl 4():iv44-49  
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
49. PMID: 26484411; 2015, Br J Cancer;113(9):1254-8  
Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
50. PMID: 24549645; 2013, J Pathol;231(4):449-56  
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
51. PMID: 24739573; 2014, Nat Rev Cancer;14(5):359-70  
Unravelling mechanisms of p53-mediated tumour suppression.
52. PMID: 21125671; 2011, J Pathol;223(2):137-46  
Haplo-insufficiency: a driving force in cancer.
53. PMID: 27998224; 2016, J Clin Oncol;34(36):4354-4361  
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
54. PMID: 26646755; 2016, Ann Oncol;27(3):539-43  
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
55. PMID: 25669829; 2015, Ann Oncol;26(5):1012-8

# ACT Onco<sup>®</sup> + Report

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.

56. PMID: 27466356; 2016, Mol Cancer Ther;15(10):2475-2485  
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
57. PMID: 23670029; 2013, Oncotarget;4(5):705-14  
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
58. PMID: 17145525; 2006, Semin Oncol;33(5 Suppl 10):S8-14  
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
59. PMID: 21399868; 2011, Int J Oncol;38(5):1445-52  
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
60. PMID: 20549698; 2011, Int J Cancer;128(8):1813-21  
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
61. PMID: 10786679; 2000, Cancer Res;60(8):2155-62  
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
62. PMID: 25672981; 2015, Cancer Res;75(7):1187-90  
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.
63. PMID: 11544175; 2001, Genes Dev;15(17):2177-96  
Cell cycle checkpoint signaling through the ATM and ATR kinases.
64. PMID: 11163154; 2001, Curr Opin Genet Dev;11(1):71-7  
ATM and ATR: networking cellular responses to DNA damage.
65. PMID: 12526805; 2002, Cell;111(6):779-89  
ATR regulates fragile site stability.
66. PMID: 10097108; 1999, Proc Natl Acad Sci U S A;96(7):3745-50  
A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage.
67. PMID: 15282542; 2004, EMBO J;23(15):3164-74  
ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background.
68. PMID: 22341969; 2012, Am J Hum Genet;90(3):511-7  
Germline mutation in ATR in autosomal- dominant oropharyngeal cancer syndrome.
69. PMID: 12640452; 2003, Nat Genet;33(4):497-501  
A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome.
70. PMID: 17879369; 2007, Genes Chromosomes Cancer;46(12):1061-8  
Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase 1 DNA damage response axis in colon cancers.
71. PMID: 16288216; 2006, Oncogene;25(14):2113-8  
Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract.
72. PMID: 11691784; 2001, Cancer Res;61(21):7727-30  
Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.
73. PMID: 19470935; 2009, J Clin Oncol;27(19):3091-6  
ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
74. PMID: 26282654; 2015, J Clin Oncol;33(33):3911-20  
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

# ACT Onco<sup>®</sup> + Report

75. PMID: 35599270; 2022, Med Oncol;39(5):96  
Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
76. PMID: 30353044; 2018, Br J Cancer;119(11):1401-1409  
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
77. PMID: 28916367; 2017, Lancet;390(10106):1949-1961  
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
78. PMID: 24095279; 2013, Mol Cell;52(4):495-505  
The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1.
79. PMID: 26342594; 2016, Fam Cancer;15(1):127-32  
Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
80. PMID: 23223565; 2013, J Clin Pathol;66(3):178-86  
Birt-Hogg-Dubé syndrome: clinicopathological features of the lung.
81. PMID: 19850877; 2009, Proc Natl Acad Sci U S A;106(44):18722-7  
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.
82. PMID: 24908670; 2014, Hum Mol Genet;23(21):5706-19  
Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation.
83. PMID: 15956655; 2005, J Natl Cancer Inst;97(12):931-5  
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.
84. PMID: 29301825; 2018, Clin Cancer Res;24(7):1546-1553  
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
85. PMID: 26418749; 2015, Oncotarget;6(32):32761-73  
Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
86. PMID: 9315668; 1997, Mol Cell Biol;17(10):6087-96  
hMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaks.
87. PMID: 16467875; 2006, Cell Res;16(1):45-54  
The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control.
88. PMID: 16385572; 2006, Int J Cancer;118(11):2911-6  
Evaluation of RAD50 in familial breast cancer predisposition.
89. PMID: 24894818; 2014, Breast Cancer Res;16(3):R58  
Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
90. PMID: 18440592; 2008, Hum Pathol;39(6):925-32  
Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival.
91. PMID: 11196187; 2001, Cancer Res;61(1):36-8  
Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability.
92. PMID: 24934408; 2014, Cancer Discov;4(9):1014-21  
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
93. PMID: 16474176; 2006, Carcinogenesis;27(8):1593-9  
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.

# ACT Onco<sup>®</sup> + Report

94. PMID: 27016230; 2016, Gynecol Oncol;141(1):57-64  
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
95. PMID: 25935112; 2015, Trends Biochem Sci;40(6):296-308  
Structural determinants of Smad function in TGF- $\beta$  signaling.
96. PMID: 19014666; 2008, Pathogenetics;1(1):2  
Smad4 haploinsufficiency: a matter of dosage.
97. PMID: 9545410; 1998, Am J Hum Genet;62(5):1129-36  
A gene for familial juvenile polyposis maps to chromosome 18q21.1.
98. PMID: 8553070; 1996, Science;271(5247):350-3  
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.
99. PMID: 8673134; 1996, Nat Genet;13(3):343-6  
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers.
100. PMID: 18662538; 2008, Cell;134(2):215-30  
TGFbeta in Cancer.
101. PMID: 9135016; 1997, Cancer Res;57(9):1731-4  
Tumor-suppressive pathways in pancreatic carcinoma.
102. PMID: 23139211; 2013, Cancer Res;73(2):725-35  
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.
103. PMID: 22810696; 2012, Nature;487(7407):330-7  
Comprehensive molecular characterization of human colon and rectal cancer.
104. PMID: 25890228; 2015, World J Surg Oncol;13():128  
Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.
105. PMID: 19841540; 2009, J Clin Invest;119(11):3208-11  
Smad4: gatekeeper gene in head and neck squamous cell carcinoma.
106. PMID: 15867212; 2005, Clin Cancer Res;11(9):3191-7  
Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
107. PMID: 25589618; 2015, Clin Cancer Res;21(6):1447-56  
Genomic analysis of metastatic cutaneous squamous cell carcinoma.
108. PMID: 29703253; 2018, BMC Cancer;18(1):479  
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
109. PMID: 28522603; 2017, Clin Cancer Res;23(17):5162-5175  
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.
110. PMID: 16144935; 2005, Clin Cancer Res;11(17):6311-6  
SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
111. PMID: 24384683; 2014, Br J Cancer;110(4):946-57  
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
112. PMID: 12237773; 2002, Br J Cancer;87(6):630-4  
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
113. PMID: 25749173; 2015, Transl Oncol;8(1):18-24

# ACT Onco<sup>®</sup> + Report

A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.

114. PMID: 19478385; 2009, Cell Oncol;31(3):169-78  
Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.
115. PMID: 25681512; 2015, J Clin Pathol;68(5):341-5  
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
116. PMID: 26861460; 2016, Clin Cancer Res;22(12):3037-47  
Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.
117. PMID: 26947875; 2016, Transl Oncol;9(1):1-7  
Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.
118. PMID: 25760429; 2015, Pancreas;44(4):660-4  
SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
119. PMID: 22504380; 2012, Pancreas;41(4):541-6  
SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
120. PMID: 19584151; 2009, Clin Cancer Res;15(14):4674-9  
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.
121. PMID: 18425078; 2008, Mod Pathol;21(7):866-75  
Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival.
122. PMID: 26703889; 2016, Lancet;387(10022):968-977  
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
123. PMID: 22149876; 2012, N Engl J Med;366(6):520-9  
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
124. PMID: 21306238; 2011, N Engl J Med;364(6):514-23  
Everolimus for advanced pancreatic neuroendocrine tumors.
125. PMID: 23158522; 2013, Lancet;381(9861):125-32  
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
126. PMID: 18653228; 2008, Lancet;372(9637):449-56  
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
127. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164  
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
128. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102  
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
129. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428  
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
130. PMID: 31157963; 2019, N Engl J Med;381(4):317-327  
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
131. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505  
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
132. PMID: 28578601; 2017, N Engl J Med;377(6):523-533  
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.



# ACT Onco<sup>®</sup> + Report

133. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284  
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
134. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589  
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
135. PMID: 30110579; 2018, N Engl J Med;379(8):753-763  
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
136. PMID: 17538086; 2007, N Engl J Med;356(22):2271-81  
Temsilolimus, interferon alfa, or both for advanced renal-cell carcinoma.